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Abstract
Photoacoustic tomography (PAT) is emerging as a novel, hybrid, and non ionizing imaging
modality, because of its satisfactory spatial resolution and high soft tissue contrast. PAT combines
the advantages of both optical and ultrasonic imaging methods. It opens up the possibilities for
non-invasive staging of breast cancer and may replace sentinel lymph node (SLN) biopsy in clinic
in the near future. In this work, we demonstrate for the first time that Copper can be used as a
contrast metal for near infrared detection of SLN using PAT. A unique strategy is adopted to
encapsulate multiple copies of Cu as organically soluble small molecule complexes within a
phospholipids-entrapped nanoparticle. The nanoparticles assumed a size of 80–90nm, which is the
optimum hydrodynamic diameter for its distribution throughout the lymphatic systems. These
particles provided at least six times higher signal sensitivity in comparison to blood, which is a
natural absorber of light. We also demonstrated that high SLN detection sensitivity with PAT can
be achieved in rodent model. This work clearly demonstrates for the first time, the potential use of
copper as an optical contrast agent.
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Photoacoustic (PA) or optoacoustic imaging is a non-invasive technique that uniquely
synergizes optical and ultrasound imaging.1–2 The technique is based on a phenomenon in
which the absorbed electromagnetic energy of light is transformed into kinetic energy and
localized heating releasing a pressure or radiofrequency wave. The optical absorption can be
associated with endogenous molecules, such as hemoglobin or melanin, or it can be
achieved through exogenously delivered contrast agents: e.g. optical dyes, gold
nanoparticles, single walled carbon nanotube (SWNT).3–5 Due to the high concentration of
hemoglobin (12 to 15 g/dl), blood inherently has a high magnitude of light absorption
compared with surrounding tissues, which routinely allows blood vessels to be visualized.
However, PA imaging of nonvascular tissues, e.g., lymph nodes, or intravascular
biosignatures, e.g., integrins, exogenous contrast agents must be employed. Of late, this
hybrid imaging modality has been successfully used for breast cancer imaging, brain
structural and functional imaging, blood oxygenation and hemoglobin monitoring, tumor
angiogenesis, and, very recently for detecting nascent angiogenic premature vessels in
rodent model .6–10
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Breast cancer spreads to one or a few lymph nodes, the sentinel lymph node(s) (SLNs),
before further metastasizing to other axillary nodes. Identification and sampling of SLN,
known as sentinel node biopsy (SLNB), successfully reduced the need for complete axillary
lymph node dissection and reduced the associated morbidities: lymphedema, nerve injury,
and shoulder dysfunction. Consequently, SLNB has become widely practiced in the United
States, Europe, and Australia. SLNB requires noninvasive detection of SLNB, which are
marked for intra operative localization and resection with methylene blue dye placed
preoperatively under imaging guidance. SLNB dye staining is approximately 90% effective,
which can be improved to over 95% with radioactive colloid labeling but the added expense
and inconvenience of handling radioactive materials and performing intraoperative gamma
imaging detracts from the technique.11–16
Interest in photoacoustic guided imaging for noninvasive axillary staging of breast cancer
reflects the low cost and increased flexible convenience of preoperative and intraoperative
imaging. In the absence of intrinsic PA contrast, exogenous contrast agents (e.g. gold
nanoparticles, indocyanine dye) must be employed to detect lymph nodes. Recently, we 17
and other groups18–21 have shown the utility of gold nanoparticles (≤ 90 nm) for enhancing
SLN detection. However, the clinical use of gold is discouraged by the high and
unpredicatable cost of the metal. Furthermore, the optical property of gold, i.e. surface
plasmon resonance is dependent on expensive and complicated chemistries to tightly control
particle surface coating and morphology. In this work, we hypothesized that copper-based
nanoparticles could provide an innovative, inexpensive and commercially viable alternative
optical contrast agent for PA imaging. Copper is presently available at ~$20/Kg in contrast
to gold, which is being sold as a pure metal at $1800/oz. We have noted the use of previous
PA contrast agents (approx. 50 nm), based on SWNT and gold nanoparticles (nanoshells,
nanorods), which provided viable photoacoustic contrast in the near-infrared (NIR) region.
However due to their “hard, crystalline” nature, the in vivo distribution and whole-body
clearance is questionable and may create regulatory barrier for clinical translation. To the
best of our knowledge, the use of Cu for PA diagnostic imaging has never been reported.
Copper as a pure metal or mineral is abundant in the Earth's crust (~ 50 ppm) and
historically available at low cost, particularly when compared with gold. In 1895, Cotton
reported that the optical activity in bivalent copper complexes was largely dependent on the
symmetry. Dissymmetry induced by d–d and d–p electronic mixings in different co-
ordinations, e.g., octahedral, tetragonal, etc, regulated the strength and the sign of optical
rotation.22 Both the absolute configuration of an asymmetric atom in a ligand and the
asymmetry of the conformation of the chelate rings contribute to the overall optical activity
of the system. We determined that a complex of Cu2+ with neodecanoic acid (NA) showed
broad near infrared (NIR) optical absorption, λ=~600–700 nm, presumably due to crystal-
field splitting as suggested by others.23–24 Since the optical signal of hemoglobin occurs at
λ=500 nm, below the bandwidth of copper neodecanoate (CuNA), we hypothesized
nanocolloids, rich in copper neodecanoate, could provide high PA contrast for sentinal
lymph node imaging.
In the past, copper nanoparticles have been synthesized using various methods including
high-temperature decomposition of organometallic precursors, supercritical carbon dioxide,
etc.22–26 Typically, these methods yield particles larger than the normal renal filtration
threshold (i.e., 6–10 nm), presenting long-term safety and regulatory challenges. Moreover,
in contradistinction to usual “solid” or “hard” copper nanoparticle constructs, we developed
a self-assembled “soft” particle synthesis derived from organically soluble Cu(II)-
neodecanoate, with a targeted size of <90nm, based on previous SLN optimization with gold
nanobeacons.17
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RESULTS AND DISCUSSION
Cu-neodecanoate complexes were mixed with polysorbates (sorbitan mono-9-octadecenoate
poly(oxy-1,2-ethanediyl) and encapsulated within a phospholipids outer layer. Polysorbate,
a nonionic surfactant derived from polyethoxylated sorbitan and oleic acid, is generally
considered safe and often used in foods.16 The hydrophilic groups in this compound were
polyethers or polyoxyethylenes. CuNA was incorporated at 20% w/v within the polysorbate
core matrix and encapsulated by 2% (v/v) phospholipids. The compatibility of CuNA with
polysorbate allowed copper particle payloads of up to 60% (w/v). The surfactant mixture
was comprised of phosphatidylcholine (lecithin-egg PC), (50 mole %), (Avanti Polar
Lipids), and polysorbates (50 mole %). Briefly, the synthesis involved the vigorous mixing
of Cu-neodecanoate (0.3g) in toluene with polysorbate, followed by the evaporation of
solvent from the mixture to produce a homogeneous suspension of CuNA in polysorbates at
80°C under reduced pressure. This product was microfluidized as a 20% (v/v) colloidal
suspension with 2% (v/v) phospholipids-polysorbate surfactant mixture in nanopure water
(Figure 1). Nanoparticles were purified by exhaustive dialysis through 10 kDa MWCO
membrane against deionized water (0.2PM) (Figure 1) to remove any unbound copper.
Nanoparticles of copper neodecanoate (NanoCuN) exhibited high shelf life stability at 4°C
with less than 5% change in particle sizes and polydispersity over 5 months. Dynamic light
scattering measurements of NanoCuN revealed a hydrodynamic diameter of 86±06 nm (Dh)
with a low polydispersity (PDI) of 0.21±0.02 (Brookhaven Instrument Co.). The negative
electrophoretic potential value of -12±07 mV, suggests a complete and successful
encapsulation of the copper-polysorbate core with surfactant.
Copper content determined by inductively coupled plasmon optical emission spectroscopy
(ICP OES), was 16.99 mg/L of the 20% colloidal suspension. The measurement of UV-vis
spectrum of NanoCuN in water revealed optical absorption wavelengths (λ) between 603 nm
to 746 nm (λmax= 683 nm), which corroborated the presence of copper complexes. The
particles were characterized in the anhydrous state by transmission electron microscopy
(TEM), atomic force microscopy (AFM), energy-dispersive X-ray spectroscopy (EDX) and
scanning electron microscopy (SEM). Using TEM, the uranyl acetate stained CuNP were
observed to be spherical with a distinct dark lipid periphery (Figure 2c). AFM particle height
was 60 ± 14 nm. NanoCuN, diluted ~1:100× with acetone, were placed as a drop on a
silicon wafer and allowed to air dry for SEM and EDX analyses. The SEM images (HV=5
kV) confirmed the spherical morphology of the nanoparticles. Elemental analysis (HV=5
kV) confirmed the presence of Cu within the sample (Figure 2f).
Copper is known to pose toxicity when used in high concentration. Therefore, it is important
to establish the safety and stability of these particles prior to their in vivo use. These particles
exhibited remarkable shelf stability with time and maintain the particle integrity for future
clinical translation. Changes in hydrodynamic diameter and electrophoretic potential were
monitored over a period of 90 days. Only insignificant variation was noticed when preserved
under argon atmosphere at 4°C. (figure 2i) The efficiency of the copper entrapment in the
particle was tested in a dissolution experiment. Nanoparticle was incubated with saline and
human plasma albumin at 37°C and the total release of the copper complex was measured
over time. The release of the copper neodecanoate was monitored by UV-vis spectroscopy
over the 600–750 nm wavelength range. Nanoparticles were shown to retain 96–97% of the
complex with only <4% release over 3 days against an infinite sink. (figure 2j) These results
confirm that copper is retained well in dissolution and no substantial in vitro release of
copper was noticed.
Since hemoglobin is a dominant optical absorber in the human body and produces strong PA
contrast, the efficacy of NanoCuN was first compared with blood in the NIR wavelength
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window. Figure 3a shows the PA signals obtained from a tygon tube (I.D. 250 μm, O.D. 500
μm) filled with CuNP (20 volume%) and whole rat blood (hematocrit ~ 45%; hemoglobin ~
15g/dl). Since the photoacoustic scanner is limited by the accessibility of laser wavelength at
670 nm, the laser was tuned to the closest excitation λ =720 nm. At this wavelength, the
peak-to-peak PA signal amplitude obtained from NanoCuN was ~650 mV, compared to
~140 mV peak-to-peak PA signal amplitude from blood alone. Figure 3b shows the PA
spectrum (peak-to-peak PA signal amplitude versus excitation light wavelength) of the
copper nanoparticles (in black) for an excitation wavelength range of 720–870 nm. The PA
spectrum of rat blood (in red) is overlaid on the same figure. The PA signal obtained from
NanoCuN was clearly much stronger than blood over the entire range of wavelengths.
Figure 3c illustrates the ratio of the peak-to-peak PA signal amplitude of NanoCuN to that of
blood between 720 and 870 nm. The PA signal from the tygon® tube filled with copper
nanoparticles is more than five times stronger than that from blood at 720 nm. Weak
hemoglobin absorption within the NIR window is well-known and exploited for deep tissue
PA imaging. A typical preparation of NanoCuN (Cu content: 16.99 mg/ml for a 20%
colloidal suspension) provided a SNR of 42 dB at 720 nm wavelength in vitro. The noise
equivalent concentration (i.e., the concentration that provides a SNR of unity) is calculated
to be ~0.4 mg/ml. The magnitude of PA signal derived from NanoCuN within the NIR
region suggests potential clinical utility for both intravascular as well as extravascular
diagnostic applications. PA signal of NanoCuN is approximately five times stronger than
that of rat blood which is either higher or comparable to gold nanoparticles in terms of the
signal strength. Interestingly, in our previous work, gold nanobeacons (GNB)17 provided 12
fold signal enhancement over blood at a concentration of 2 wt/v% in contrast to 0.02 wt/v%
for the copper nanoparticles used in the present study. In addition, this platform presents the
flexibility to optimize the metal loading and can easily be increased at least to 2 wt/v%.
More in depth study is warranted to understand comparative molar absorptivities and PA
signal of the system, which is presently under progress in our laboratories.”
Our previous work for gold nanocages demonstrated the PA system could detect the SLN as
deep as ~33 mm.18–20 Figure 4a shows a representative digital photograph of a rat taken
prior to image acquisition. The axillary skin was shaved prior to PA imaging. Before
NanoCuN administration, a baseline (i.e., control PA image) was obtained, which is
presented as a maximum intensity projection (MIP, Figure 4b). The vasculature, denoted as
BV, was sharply imaged (500 μm × 500 μm in plane resolution), but no lymph node(s) were
visible at baseline. However, as shown in Figure 4c, PA imaging of the same region of
interest immediately after the NanoCuN injection into the paw prominently revealed the
SLN not previously apparent; at 60 min post-injection (Figures 2d) the magnitude of PA
contrast was further enhanced, reflecting a substantial increase in NanoCuN uptake by the
draining SLN. Figure 4(e) presents a digital photograph of the same animal with the skin
excised following the PA imaging experiment. Excised lymph node was analytically tested
for copper by ICP-OES, which revealed the copper content to be 0.2415 mg/L, 60 minutes
post injection.
The preliminary bio-distribution of these particles was studied in a rat model. Following
intravenous injection (1ml/kg, 20 vol% of nanoparticles), animals (n=2) were sacrificed at
2h and 24h post injection. The major organs (i.e. liver, spleen, heart, lung, muscle and
kidney) were collected, weighed and digested. The concentration of copper in the digested
sample was determined by ICP-OES (Figure 4a). Results indicate anticipated clearance of
the particle through reticuloendothelial system (RES) as marked by the high copper
accumulation in spleen, liver, and kidney. Kidney and feces accumulated 19.7±4.4 and
12.6±0.5 % injected dose (ID)/g of tissue, whereas liver and lung gathered 14.2±1.9 and
4.3±0.1% ID/g of tissue. Other major organs accumulated smaller amounts of NanoCuN at
2h post injection. Spleen, heart, and muscle accumulated 3.9±0.8, 7.1±0.5 and 1.8±0.9 %
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ID/g of tissue, respectively. At 24 h after NanoCuN injection, feces, liver and kidney
accumulated 26.2±3, 23.7±2.1 21.3±7 % ID/g of tissue respectively (Figure 5) and were the
major sites of nanoparticle build up. Other major organs, i.e. spleen, heart and muscle
accumulated 1.6±0.4, 2.1±0.3 and 0.6±0.1 % ID/g of tissue, respectively after 24h post
injection. More comprehensive study to understand their in vivo distribution is presently
under progress.
CONCLUSION
These data, for the first time, clearly demonstrate the potential use of copper as contrast
agents for identification of SLNs with photoacoustic scanning systems. To the best of our
knowledge, there is only one previous report of using copper sulfide nanoparticles as a
photothermal agent.27–28 Copper neodecanoate, by virtue of its unique optical properties
within in the NIR range, provided substantial PA contrast, and in contradistinction to “hard”
copper particle approaches, allowed facile synthesis of “soft” agents with stable, readily
excreted small molecule complexes. Although there are reports of toxicity from copper,29
the design of these nanoagents allowed us to incorporate hydrophobic copper complexes in a
highly stable manner. NanoCuN produced nearly five times more signal than blood as a 20%
colloidal suspension. NanoCuN offered rapid sentinel lymph nodes detection in rats in
comparison to gold nanorods. At a concentration of 1 PM, gold nanorods (10 nm in diameter
and 41 nm in length) were shown to follow a much slower kinetics in rodent model and took
more than 20 h to be observed at SLNs.20 These results suggest that enhanced sentinel
lymphnode PA imaging is possible with nanoparticles of copper neodecanoate.
METHODS
Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical
Co. (St. Louis, MO) and used as received. Anhydrous chloroform was purchased from
Aldrich Chemical Co. and distilled over calcium hydride prior to use. High purity egg yolk
phosphatidylcholine were purchased from Avanti Polar Lipids, Inc. Cholesterol, sorbitan
sesquioleate were purchased and used as received from Aldrich Chemical Co. (St. Louis,
MO). Cu(III)-neodecanoate was purchased from Spectrum Chemicals, Inc. and used as
received. Argon and nitrogen (UHP, 99.99%) were used for storage of materials. The
Spectra/Por membrane (Cellulose MWCO: 10 000 Da) used for dialysis was obtained from
Spectrum Medical Industries, Inc. (Laguna Hills, CA).
Preparation of copper neodecanoate nanoparticles
NanoCuN were prepared by suspending copper neodecanoate (0.3 g in 60% toluene Aldrich
Chemicals, Inc.) in sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl (5 ml, Aldrich
Chemicals, Inc.,), and vigorously vortexing the mixture to homogeneity. The toluene was
evaporated off under reduced pressure at 80 °C. The surfactant co-mixture included high
purity egg yolk phosphatidylcholine (80 mole%, 281 mg), sorbitan mono-9-octadecenoate
poly(oxy-1,2-ethanediyl (20 mole%, 124 mg). The surfactant co-mixture was dissolved in
chloroform, evaporated under reduced pressure, dried in a 50°C vacuum oven overnight, and
dispersed into water by probe sonication. This suspension was combined with the copper
polysorbate mixture (20% v/v), distilled, de-ionized water (77.3% w/v) and glycerin (1.7%,
w/v). The mixture is continuously processed thereafter at 20,000 PSI for 4 minutes with an
S110 Microfluidics emulsifier (Microfluidics). The nanoparticles were dialyzed against
water using a 10,000 Da MWCO cellulose membrane for prolonged period of time and then
passed through a 0.45 Pm Acrodisc Syringe filter. The nanoparticles are stored under argon
atmosphere typically at 4°C in order to prevent any bacterial growth.
Pan et al. Page 5
ACS Nano. Author manuscript; available in PMC 2013 February 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
DLS (Dav)/nm =86±06 nm; Zeta (ζ)/mV = −12±05 mV; TEM (Dah)/nm=97±30; AFM
(Hav)/nm =60±14 nm, PDI=0.22±0.02, UV-VIS spectroscopy (λmax) = 603–746 nm, ICP-
OES= 16.99 mg of Cu /L.
Dynamic light scattering measurements
Hydrodynamic diameter distribution and distribution averages for the copper nanoparticles
in aqueous solutions were determined by dynamic light scattering. Hydrodynamic diameters
were determined using a Brookhaven Instrument Co. (Holtsville, NY) Model Zeta Plus
particle size analyzer. Measurements were made following dialysis (MWCO 10 kDa dialysis
tubing, Spectrum Laboratories, Rancho Dominguez, CA) of NanoCuN in deionized water
(0.2 mM). Nanoparticles were dialyzed into water prior to analysis. Scattered light was
collected at a fixed angle of 90°. A photomultiplier aperture of 400 mm was used, and the
incident laser power was adjusted to obtain a photon counting rate between 200 and 300
kcps. Only measurements for which the measured and calculated baselines of the intensity
autocorrelation function agreed to within +0.1% were used to calculate nanoparticle
hydrodynamic diameter values. All determinations were made in multiples of five
consecutive measurements.
Electrophoretic potential measurements
Electrophoretic (Zeta) potential (z) values for the NanoCuN were determined with a
Brookhaven Instrument Co. (Holtsville, NY) model Zeta Plus zeta potential analyzer.
Measurements were made following dialysis (MWCO 10 kDa dialysis tubing, Spectrum
Laboratories, Rancho Dominguez, CA) of NanoCuN suspensions into water. Data were
acquired in the phase analysis light scattering (PALS) mode following solution equilibration
at 25°C. Calculation of z from the measured nanoparticle electrophoretic mobility (ζ)
employed the Smoluchowski equation: μ = εζ/η, where ε and η, are the dielectric constant
and the absolute viscosity of the medium, respectively. Measurements of ζ were
reproducible to within ±4 mV of the mean value given by 16 determinations of 10 data
accumulations.
Stability of the nanocolloids
Long-term shelf-stability of the nanocolloids was assessed by measuring hydrodynamic
diameter distributions over a period of >60 days from the time of synthesis for different
replicates of YbNC formulations preserved under inert atmosphere (i.e. argon) at 4°C.
Changes in particle size and polydispersity indexes due to Ostwald ripening were minimal
(< 7%) over the observation period.
Inductively coupled plasma-optical emission spectroscopy
The copper (Cu) content of NanoCuN was analyzed by inductively coupled plasma-optical
emission spectroscopy (ICP-OES, Perkin Elmer Optima 7000). The samples were treated
with a mixture of conc. nitric acid, conc. hydrochloric acid and hydrogen peroxide followed
by digestion using Multiwave 3000 (Anton Paar, USA).
Animal studies
Guidelines on the care and the use of laboratory animals at Washington University in St.
Louis were followed for all animal experiments. Initial anesthetization of rat was done using
a mixture of ketamine (85 mg/kg) and xylazine (15 mg/kg) and maintained on 0.75–1.0%
isoflurane delivered through a calibrated vaporizer. NanoCuN was administered (1ml/kg;
total volume) intravenously through tail vein catheter. The major organs were independently
frozen, ground to tissue homogeneity, weighed, digested and the entire specimen was
analyzed for Cu content using ICP-OES.
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Photoacoustic spectroscopy
Light source: tunable Ti:sapphire laser (720nm, LT-2211A, LOTIS TII) pumped by a Q-
switched Nd:YAG (LS- 2137/2, LOTIS TII); pulse width <15 ns, pulse repetition rate 10
Hz. The incident laser fluence on the sample surface was controlled to conform to the
American National Standards Institute standards. Transducer: 5 MHz central frequency,
spherically focused, 2.54 cm focul length; 1.91 cm diameter active area element, 72%
bandwidth (V308, Panametrics-NDT); low-noise amplifier (5072PR, Panametrics- NDT).
Data were acquired with a digital oscilloscope (TDS 5054, Tektronix).
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Figure 1.
Synthesis and physico-chemical characterization of self-assembled nanoparticles of copper
neodecanoate (a) Schematic describing the preparation of copper-enriched nanoparticles: (i)
Suspension of copper neodecanoate (1) in sorbitan sesquioleate, vigorously vortex and
mixing, filter using cotton bed, vortex; (ii) dissolve phospholipids in anhydrous chloroform
and preparation of phospholipids thin film by slow evaporation of solvent at 45°C under
reduced pressure; (iii) resuspension of the thin film in water (0.2 PM); (iv) self-assenbly by
high pressure homogenization at 4°C, 20,000 psi (141 MPa), 4 min, v) dialysis (cellulosic
membrane, MWCO 20K).; in box: characterization table for nanoparticles of copper
neodecanoate.
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Figure 2.
(a) Hydrodynamic particle size distribution from DLS; (b) UV-vis spectrum of NanoCuN
nanoparticles in water; (c) anhydrous state TEM image; (d–e) SEM images; (f) EDX
spectrum of the selected area from the image in (e); (g) AFM image (deposited on glass
substrate); shelf life stability of NanoCuN over 90 days from formulation; (i) dissolution of
Cu over three days when incubated with saline and human plasma albumin.
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Figure 3.
a) PA spectroscopy signals generated from a tygon® tube (I.D. 250 μm, O.D. 500 μm) filled
with NanoCuN (20% colloidal suspension and rat blood. The laser was tuned to 720 nm
wavelength. b) Comparative PA spectra of NanoCuN and rat blood over a 720–870 nm NIR
wavelength range; c) Ratio of the peak-to-peak PA signal amplitudes generated from
NanoCuN to those of blood over a range of 720–870 nm.
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Figure 4.
Non-invasive in vivo PA images (maximum intensity projections, MIP) of the SLN in a rat.
a) Photograph of the rat with region of interest depilated before scanning. The scanning
region is delineated by a black dotted square. b) Baseline PA image acquired before
NanoCuN injection. Bright regions represent inherent optical absorption from a blood vessel
(BV). c) PA image (MIP) acquired almost immediately after NanoCuN administration. d) 60
min post-injection PA image showing a marked signal enhancement corresponding to
increased NanoCuN uptake by the node: Blood vessel (BV) and sentinel lymph node (SLN)
are marked with arrows. The SLN is visible in both c) and d), however, not apparent in b). e)
Photograph of the rat with the skin excised after PA imaging. For b)–d): FOV = 25 mm × 24
mm, step size along the X direction = 0.2 mm, step size along the Y direction = 0.4 mm,
total scan time=~23 min. No signal averaging was used.
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Figure 5.
Preliminary bio-distribution of NanoCuN in rats: distribution of copper (NanoCuN) in major
organs determined by ICP-OES at 2 and 24 h following intravenous injection of
nanoparticles (1 mg/mL of 20% colloidal suspension). Distribution of copper in major
organs (liver, kidney, spleen, lung, heart and muscle) is expressed as % injected dose/g of
tissue.
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